


PHARMACEUTICAL 2018

Evofem Biosciences Inc. Rank 338 of 349





PHARMACEUTICAL 2018

Evofem Biosciences Inc. Rank 338 of 349

The relative strengths and weaknesses of Evofem Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evofem Biosciences Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 141% points. The greatest weakness of Evofem Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 783% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,360%, being 1,082% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	4,025
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,412
Liabilities, Non-Current	0
Other Assets	93
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	51
Property and Equipment	0
Research and Development	3,946
Revenues	0
Selling, General and Administrative Expense	6,099

Output Variable	Value in 1000 USD
Assets	4,119
Liabilities	1,412
Expenses	10,045
Stockholders Equity	2,707
Net Income	-9,993
Comprehensive Net Income	-9,993
Economic Capital Ratio	-1,360%